Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia Alessandra Bettiol,Ettore Marconi, Niccolò Lombardi, Giada Crescioli, Filippo Gherlinzoni, Thomas Walley, Alfredo Vannacci, Alessandro Chinellato, Pietro Giusti Background and Objectives First-line treatment of chronic phase (CP) chronic myeloid leukemia (CML) is based on the first-generation tyrosine kinase inhibitor (TKI) imatinib…
